相关实验视频
Updated: Jul 31, 2026

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
13.0K
降低心力衰竭的II期临床试验风险:JACC的立场论文:基础到翻译科学和心力衰竭协作室
Douglas L Mann1, G Michael Felker2, Ellis F Unger3
1Washington University School of Medicine, St. Louis, Missouri, USA.
JACC. Basic to translational science
|May 28, 2025
概括
二期临床试验对于药物开发至关重要,建立概念验证和评估安全性. 然而,这些试验存在局限性,不能完全预测新疗法的后期结果.
科学领域:
- 心血管医学 心血管医学
- 临床药理学 临床药理学
- 药物开发 药物开发
背景情况:
- 二期临床试验是药物开发的关键,为决策提供了必要的数据.
- 关键目标包括建立概念验证,评估药理动力学,药理动力学,安全性和剂量反应关系.
研究的目的:
- 检查药物开发中的第二阶段计划的价值和限制.
- 为研究人员和赞助商提供见解,以减轻治疗候选人的去/不去决策中的风险.
主要方法:
- 对II期临床试验方法和目标的审查.
- 分析二期研究固有的局限性.
- 使用来自心力衰竭试验的案例.
主要成果:
- 第二阶段试验提供了关键的概念验证和安全数据.
- 这些试验为推进候选药物的去/不去决定提供了信息.
- 第二阶段的结果并不能完全预测第三阶段的成功.
结论:
- 了解二期试验的局限性对于准确的风险评估至关重要.
- 第二阶段计划的战略规划可以提高药物开发的成功率.
- 本文旨在通过分析二期试验价值和约束来降低去/不去决策的风险.
相关概念视频
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

